Zevra Therapeutics Receives FDA Acceptance Of Resubmission Of NDA For Arimoclomol As A Treatment For Niemann-Pick Disease Type C
Read the full statement from Zevra Therapeutics here:
Here is a summary of the article:
Zevra Therapeutics Resubmits NDA for Arimoclomol: The company announced that the FDA has accepted the resubmission of the NDA for arimoclomol, a potential treatment for Niemann-Pick disease type C.
PDUFA Action Date and Advisory Committee: The FDA has assigned a PDUFA action date of June 21, 2024, and intends to present the resubmission for discussion in an advisory committee.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia: